Form 4: Inari Medical CEO Andrew Hykes Reports Stock Sale and Tax Withholdings

Andrew Hykes, CEO of Inari Medical, reports a sale of 3,000 shares and several transactions related to tax obligations from vesting restricted share units.

Summary

• Andrew Hykes, the President and CEO of Inari Medical, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On July 1, 2024, Hykes sold 3,000 shares of common stock at a price of $50.08 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 13, 2023.
• Additional transactions on the same day involved the withholding of shares by Inari Medical to cover tax obligations related to the vesting of restricted share units awarded in 2021, 2022, 2023 and 2024.
• Following these transactions, Hykes directly owns 458,252 shares of Inari Medical common stock.
• He also indirectly owns 1,550 shares through each of his three children and 1,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. The sale is under a pre-arranged plan and tax witholdings are routine, so it's neutral.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The sale was executed under a pre-arranged 10b5-1 trading plan.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, but the pre-arranged nature of the sale mitigates concerns.
• The tax withholding impacts the executive's personal finances.

Key Dates